Sangamo Therapeutics (SGMO) Misses Q1 EPS by 2c, Revenues Beat

Sangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.32), $0.02 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $26.28 million versus the consensus estimate of $23.98 million.

“This quarter, we have continued our focus on advancing our lead programs through clinical execution, regulatory interactions, and collaborations with our partners and investigators. We are pleased that enrollment has completed for Pfizer’s lead-in study for the hemophilia A Phase 3 AFFINE trial. Additionally, the EMA granted Orphan Designation and the FDA granted Fast Track Designation to BIVV003, now known as SAR445136, our cell therapy product candidate treating sickle cell disease partnered with Sanofi. Also, we initiated the STEADFAST study for our product candidate treating renal transplant rejection, which we believe is the first-in-human CAR-Treg clinical study,” said Sandy Macrae, Chief Executive Officer of Sangamo. “Further, our research engine continued to be highly productive this quarter, advancing both our CAR-Treg programs for autoimmune disorders and our transcriptional regulation therapies for neurological diseases.”

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• U.S. Bank hires Eric Levine to head healthcare payments unit
• Cushman & Wakefield names two capital markets leaders in APAC